[The complexity of chronic pelvic pain exemplified by the condition currently called interstitial cystitis. Part 2: Treatment].
The so-called interstitial cystitis is a chronic pain syndrome rather than a purely end organ disease of the urinary bladder. New suggestions for definitions and nomenclature take this into consideration. Since aetiology and pathogenesis are still unknown a treatment of the cause is still not possible. There are neither evidence-based treatment algorithms nor a so-called standard therapy. Numerous therapeutic approaches have been tried up to now. These attempts can be divided into oral, intravesical, surgical and physical procedures. There are also meaningful supplementary therapy procedures beyond the boundaries of classical school medicine. The WHO staging scheme provides the basis for every pain therapy. For the oral therapeutic procedures in current use the following medications with differing levels of evidence have been recommended: amitriptylin, hydroxyzin, pentosan polysulfate. Many other orally administered drugs have also been used although in many cases evidence of efficacy is lacking, these included anticonvulsants, L-arginine and various immunomodulators and immunosuppressants. Among the intravesical therapeutic procedures botulinum toxin A, dimethyl sulfoxide, heparin and glycosaminoglycan substitutes have been used. For the physical procedures, besides bladder distension, hyperbaric oxygen therapy shows efficacy. When the conventional therapeutic methods fail, surgical (partial) removal of the urinary bladder or urinary diversion procedures represent the therapeutic ultimo ratio. There are hardly any controlled studies on alternative curative procedures although rather good results have been obtained in chronic pelvic pain syndrome with acupuncture as an additional therapeutic modality.
Binder
I
I
Schwerpunkt für Neuro-Urologie, Urologische Universitätsklinik, Marienhospital Herne, Ruhr-Universität Bochum.
Rossbach
G
G
van Ophoven
A
A
D000283:Administration, Intravesical; D000284:Administration, Oral; D000639:Amitriptyline / Q000627:therapeutic use; D001120:Arginine / Q000627:therapeutic use; D019274:Botulinum Toxins, Type A / Q000627:therapeutic use; D002908:Chronic Disease; D015653:Cystectomy; D018856:Cystitis, Interstitial / Q000209:etiology / Q000628:therapy*; D004106:Dilatation; D004121:Dimethyl Sulfoxide / Q000627:therapeutic use; D019317:Evidence-Based Medicine; D006025:Glycosaminoglycans / Q000627:therapeutic use; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D006919:Hydroxyzine / Q000627:therapeutic use; D006931:Hyperbaric Oxygenation; D007155:Immunologic Factors / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D017699:Pelvic Pain / Q000209:etiology*; D010426:Pentosan Sulfuric Polyester / Q000627:therapeutic use; D016896:Treatment Outcome; D014547:Urinary Diversion
D006025:Glycosaminoglycans; D007155:Immunologic Factors; D007166:Immunosuppressive Agents; D000639:Amitriptyline; D006919:Hydroxyzine; D010426:Pentosan Sulfuric Polyester; D006493:Heparin; D001120:Arginine; D019274:Botulinum Toxins, Type A; D004121:Dimethyl Sulfoxide